BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals

Study Status

Open to Enrollment

Study Description

This clinical trial will study how well allogeneic transplant treats blood cancers in people with HIV. The blood cancers included in this study are: acute myeloid or lymphocytic leukemia (AML or ALL), myelodysplastic syndrome (MDS), Hodgkin lymphoma and non-Hodgkin lymphoma.

An allogeneic transplant uses blood-making cells from a family member or an unrelated donor to remove and replace the abnormal blood cells in the patient. An allogeneic transplant is a common treatment for people with blood cancer that has either returned/relapsed or does not respond well to other treatments (refractory).

Study participation will last for 2 years after the transplant. 

Disease Status and/or Stage

Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People



Key Eligibility

  • Men and women age 15 or older
  • HIV-positive
  • Willing to comply with effective anti-retroviral therapy (ART)
  • Diagnosed with:
    • Acute Myeloid or Lymphocytic Leukemia (AML or ALL)
    • Myelodysplastic syndrome (MDS)
    • Hodgkin lymphoma
    • Non-Hodgkin lymphoma
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Tsiporah Shore, MD


Protocol ID

BMT CTN 0903

Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page